MALVERN, Pa., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life ...

MALVERN, Pa., March 25, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of ...

MALVERN, Pa., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for ...

Neuronetics, Inc. STIM recently announced the FDA 510(k) clearance of NeuroStar Advanced Therapy for usage as a supplement to treat major depressive disorder (MDD) in adolescents aged between 15 and ...

NeuroStar is an offering of Neuronetics, a vertically integrated medical technology and healthcare company focused on neurohealth therapies. The expansion is effective immediately, nearly one year ...

Neuronetics said there are an estimated 4.3 million people in the U.S. between the ages of 15 and 21 who have major depressive disorder. (Getty Images) Cigna's Evernorth unit is expanding coverage for ...

NeuroStar Advanced Therapy is a transcranial magnetic stimulation system that uses magnetic fields to induce neural activity in the cerebral cortex. The Food and Drug Administration (FDA) has cleared ...

Neuronetics, a medtech company focused on neurohealth disorders, today announced the FDA clearance of its NeuroStar Advanced Therapy for use as an adjust for the treatment of major depressive disorder ...

MALVERN, Pa., Nov. 13, 2018 /PRNewswire/ -- NeuroStar® Advanced Therapy, the established leader in transcranial magnetic stimulation (TMS), announced an expanded partnership with GRW Health, the ...

The new clearance is for Neuronetics’ OCD MT Cap, an add-on coil device that speeds up the process used to prepare the patient for treatment with the NeuroStar system. (iStock / Getty Images Plus) ...